Streamlining Medicaid Tecentriq Prior Authorization

Tecentriq: A Key Oncology Therapy in Medicaid

Tecentriq (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody, an immunotherapy agent used across various oncology indications, including non-small cell lung cancer, hepatocellular carcinoma, and urothelial carcinoma. As a high-cost specialty medication, Tecentriq is a frequent target for prior authorization across all payer types, including Medicaid managed care plans and state Fee-for-Service programs.

Medicaid's Dual Prior Authorization Pathways

Medicaid benefits are administered through two primary models: Fee-for-Service (FFS) and Managed Care. While FFS programs route prior authorization requests directly to the state Medicaid agency's fiscal agent, the majority of Medicaid beneficiaries are enrolled in managed care organizations (MCOs). These MCOs, such as Centene subsidiaries, Molina, or UHC Community Plan, administer benefits and manage PA workflows according to their specific criteria, which must align with or be less restrictive than the state Medicaid program's guidelines.

Navigating Tecentriq PA Requirements for Medicaid Members

Prior authorization requirements for Tecentriq under Medicaid are highly state-specific and further nuanced by individual MCO policies. Medical necessity criteria, formulary tier placement, step therapy protocols, and quantity limits are common considerations. Clinics must consult the relevant state Medicaid agency's policy library and the specific MCO's provider portal for the most current criteria to ensure compliant submissions. Klivira's platform is engineered to identify the responsible delivery model and MCO, applying the correct state and MCO rules as the floor for criteria.

Common Channels for Medicaid Tecentriq Prior Authorization Submission

• **State Medicaid Portal:** Used for Fee-for-Service (FFS) submissions, routing directly to the state Medicaid agency.
• **MCO Provider Portals:** Each Medicaid managed care organization maintains its own provider portal for PA submissions.
• **X12 278 Routing:** Where supported by the state Medicaid program or specific MCOs, electronic submission via X12 278 offers a standardized channel for prior authorization requests.

Addressing Potential Denials and Appeals for Tecentriq in Medicaid

Denials for Tecentriq prior authorizations under Medicaid often stem from insufficient clinical documentation, failure to meet medical necessity criteria, or non-adherence to formulary or step therapy requirements. When a denial occurs, the appeal pathway typically involves an initial internal review process with the MCO, followed by the option for a state fair hearing if the MCO's internal appeal is unsuccessful. Robust documentation and clear communication of medical rationale are paramount throughout this process.

Klivira's Automation for Medicaid Tecentriq PA

Klivira automates the complex process of Medicaid Tecentriq prior authorization by integrating directly with EMRs and connecting to diverse payer channels, including state Medicaid portals and MCO provider portals. Our platform intelligently routes requests, applies relevant state and MCO-specific criteria, and facilitates data exchange to accelerate approvals. This approach significantly reduces manual effort, minimizes errors, and improves turnaround times for critical oncology treatments.